Spotify
YouTubeA shared assessment of the efficacy and safety of new medicines across all 27 EU member states, designed to streamline and standardise how medicines are evaluated – the Joint Clinical Assessment (JCA) promises a major milestone in EU health policy. But now, one year since its been operationalised, how well is JCA working in practice?
Grace Hampson is joined by Patrick Hopkinson, founder of PHTA Consulting and global market access expert, and Matthias Hofer, Senior Principal Economist at OHE, to take stock of the first year of JCA.
They’ll discuss:
- Lessons learned after a year of JCA
- The PICO problem, and how drug companies are responding to it
- JCA’s expanded scope: orphan medicines, antibiotics, and vaccines
- Implications for patient access, and what’s next on the horizon
Speakers
Listen to the episode
Never miss an episode
Subscribe to our mailing list to get the latest episode